HOME > 研究案内 > 発表論文

研究案内

発表論文

2024年

  1. Hirai T, Asano K, Ito I, Miyazaki Y, Sugiura H, Agirbasli M, Kobayashi S, Kobayashi M, Shimada D, Natsume I, Kawasaki T, Ohba T, Tajiri S, Sakamaki F, Mineshita M, Takihara T, Sekiya K, Tomii K, Tomioka H, Kita H, Nishizaka Y, Fukui M, Miyata T, Harigae H : A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19. Sci Rep. 2024 Jan 2;14(1):165. doi: 10.1038/s41598-023-50445-1.
  2. Sano H, Fujino N, Numakura T, Yamada M, Tode N, Sugiura H：Acquisition of Amikacin Resistance during Amikacin Liposome Inhalation Suspension Add-on Therapy for Mycobacterium avium Complex-Pulmonary Disease. Ann Am Thorac Soc. 2024 Jan 29. doi: 10.1513/AnnalsATS.202305-454RL. Online ahead of print.
  3. Ito T, Ichikawa T, Yamada M, Hashimoto Y, Fujino N, Numakura T, Sasaki Y, Suzuki A, Takita K, Sano H, Kyogoku Y, Saito T, Koarai A, Tamada T, Sugiura H：CYP27A-27-hydroxycholerterol axis in the respiratory system contributes to house dust mite-induced allergic airway inflammation. Allegol Int.2024 Jan ;73(1):151-163. doi: 10.1016/j.alit.2023.08.005.
  4. Tsukita Y, Tozuka T, Kushiro K, Hosokawa S, Sumi T, Uematsu M, Honjo O, Yamaguchi O, Asao T, Sugisaka J, Saito G, Shiihara J, Morita R, Katakura S, Yasuda T, Hisakane K, Miyauchi E, Morita S, Kobayashi K, Asahina H : Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2024 Mar 7:e236277. doi: 10.1001/jamaoncol.2023.6277. Online ahead of print.
  5. Tsukita Y, Taguri M, Goto Y, Hosomi Y, Mizutani T, Watanabe K, Yoh K, Takahashi S, Kubota K, Kunitoh H : Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older ('MONEY' trial). Jpn J Clin Oncol. 2024 Mar 22:hyae032. doi: 10.1093/jjco/hyae032. Online ahead of print.
  6. Saito T, Fujino N, Kyogoku Y, Yamada M, Okutomo K, Ono Y, Konno S, Endo T, Itakura K, Matsumoto S, Sano H, Aizawa H, Numakura T, Onodera K, Okada Y, Hussell T, Ichinose M, Sugiura H : Identification of Siglec-1-negative alveolar macrophages with pro-inflammatory phenotypes in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2024 Mar 26. doi: 10.1152/ajplung.00303.2023. Online ahead of print.

 

このページの先頭へ

 

2023年

  1. Ebina-Shibuya R, Leonard WJ：Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023 Jan;23(1):24-37 doi: 10.1038/s41577-022-00735-y
  2. Narita D, Ebina-Shibuya R, Miyauchi E,Tsukita Y,Saito R, Murakami K, Kimura N, Sugiura H:Antibody response to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment. Respire Investg. 2023 Mar;61(2):247-253.doi: 10.1016/j.resinv.2022.11.005.
  3. Ebina-Shibuya R, Leonard WJ：TSLP-targeting therapy: Beyond allergy? Clin Transl Med. 2023 May;13(5):e1241. doi: 10.1002/ctm2.1241.
  4. Aizawa H,Fujino N, Matsumoto S, Sano H, Saito T, Hatakeyama T, Kyogoku Y, Ichikawa T, Koarai A, Horino S, Miura K, Sugiura H:A survey on medical care for allergic diseases in MIYAGI. Arerugi.2023;72(1):26-36. doi:10.15036/arerugi.72.26.
  5. Iwasaki Y, Takei Y, Yamada M, Sugino S, Saito K, Aoyagi T, Oshima K, Kanamori H, Baba H, Takei K, Tokuda K, Kodama EN, Kamo T, Kamio T, Kasai T, Ogawa S, Yamauchi M. Circulating Extracellular Vesicle Levels in Patients with Coronavirus Disease 2019 Coagulopathy: A Prospective Cohort Study. J Clin Med 2023 May 14;12(10):3460. doi: 10.3390/jcm12103460.
  6. Matsunaga T, Sano H, Takita K, Morita M, Yamanaka S, Ichikawa T, Numakura T, Ida T, Jung M, Ogata S, Yoon S, Fujino N, Kyogoku Y, Sasaki Y, Koarai A, Tamada T, Toyama A, Nakabayashi T, Kageyama L, Kyuwa S, Inaba K, Watanabe S, Nagy P, Sawa T, Oshiumi H, Ichinose M, Yamada M, Sugiura H, Wei FY, Motohashi H, Akaike T：Supersulphides provide airway protection in viral and chronic lung diseases. Nat Commun.2023Jul 25;14(1)：4476. doi:10.1038/s41467-023-40182-4.
  7. Ohe T, Yamada M, Hozawa A,Nakaya N, Nakamura T, Tsuchiya N, Narita A, Kogure M, Fuse N, Kuriyama S, Mitsune A, Suzuki A, Matsumoto S, Hatakeyama T, Iwasaki C, Suzuki M, Fujino N, Numakura T, Ichikawa T,Koarai A, Tamada T, Yamamoto M, Ichinose M, Sugiura H：Associations between birth weight and lung function in a Japanese adult population ：The tohoku medical megabank community-based cohort study. Respir Investig. 2023 Jul 8;61(5):588-600. doi: 10.1016/j.resinv.2023.06.004.
  8. Ono Y, Tsukita Y, Fujino N, Sugiura H： A case of IgA Vasculitis during Atezolizumab treatment.　Inter Med.2023： 2–3. doi:10.2169/internalmedicine.2343-23.
  9. Saito T, Kobayashi S, Okutomo K, Miura T, Ohori H, Yanai M.: Multiple cavitary lung lesions from colorectal cancer responding to chemotherapy. Respir Med. Case Reports 2023; 44: 101865.
  10. Takase M, Yamada M, Nakamura T, Nakaya N, Kogure M, Hatanaka R, Nakaya K, Chiba I, Kanno I, Nochioka K, Tsuchiya N, Hirata T, Hamanaka Y, Sugawara J, Kobayashi T, Fuse N, Uruno A, Kodama EN, Kuriyama S, Tsuji I, Hozawa A. ：Combined fat mass and fat-free mass indices and lung function among Japanese population: The Tohoku Medical Megabank Community-based Cohort Study. J Epidemiol 2023. DOI: 10.2188/jea.JE20220355
  11. Takase M, Yamada M, Nakamura T, Nakaya N, Kogure M, Hatanaka R, Nakaya K, Chiba I, Kanno I, Nochioka K, Tsuchiya N, Hirata T, Hamanaka Y, Sugawara J, Kobayashi T, Fuse N, Uruno A, Kodama EN, Kuriyama S, Tsuji I, Hozawa A. ：Association between lung function and hypertension and home hypertension in a Japanese population: the Tohoku Medical Megabank Community-Based Cohort Study. J Hypertens.2023; 41: 443-452.
  12. Tamada T, Sugiura H：Addressing therapeutic inertia for asthma biologics：Lessons from the KOFU study. Respir Investig.2023;6:815-823.
  13. Tomomatsu K, Yasuba H, Ishiguro T, Imokawa S, Hara J, Soeda S, Harada N, Tsurikisawa N, Oda N, Katoh S, Numata T, Sugino Y, Yamada M, Kamimura M, Terashima T, Okada N, Tanaka J, Oguma T, Asano K. Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis. Sci Rep. 2023; 13: 5468.
  14. Shibata Y, Kawayama T, Muro S, Sugiura H; members of Japanese Respiratory Society COPD Guideline 6th Edition Editing Committee：Management goals and stable phase management of patients with chronic obstructive pulmonary diseases in the Japanese respiratory society guideline for the management of chronic obstructive pulmonary disease 2022(6th edition ). Respir Investig. 2023 Nov;61(6):773-780. doi:10.1016/j.resinv.2023.08.007. Equb 2023 Sep 21
  15. Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Yokoi T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Hara S, Saito G, Miura S, Kanazu M, Akamatsu H.： Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility. JAMA Netw Open2023; 6(2)：e230698. doi:10.1001/jamanetworkopen.2023.0698
  16. Inomata M, Kawashima Y, Saito R, Morinaga D, Nogawa H, Sato M, Suzuki Y, Yanagisawa S, Kikuchi T, Jingu D, Yoshimura N, Harada T, Miyauchi E. ： A retrospective study of the efficacy of combined EGFR TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR TKI monotherapy for PD L1 positive EGFR mutant non small cell lung cancer: North Japan Lung Cancer Study Group 2202. Oncol Lett.2023 Jun 20; 26(2):334. doi.10.3892/ol.2023.13920
  17. Kawamura M, Shirota H, Niihori T, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma, H, Kikuchi A, Tada H, Shimada M, Kawamorita N, Kanamori M, Sugiyama I, Tsubata M, Ichikawa H, Yasuda J, Furukawa T, Aoki Y, Ishioka C. : Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility. Journal of human genetics2023；68(6)：399–408. https://doi.org/10.1038/s10038-023-01133-5
  18. Kawashima Y, Ishimoto O, Miyauchi E, Sakakibara T, Harada T, Usui K, Inoue A, Sugawara S. : Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101. Thorac Cancer2023Sep; 14(27):2804-2810. doi:10.1111/1759-7714.15076
  19. Murata　Y, Tanzawa　S, Misumi　T, Yoshioka H, Miyauchi E, Ninomiya K, Takeshita　M, Ito K, Okamoto　T, Sugawara　S, Kawashima　Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Seki N.:Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study. JTO Clin Res Rep.2023 Oct 24;4(12):100593. doi:10.1016/j.jtocrr.2023.100593
  20. Watanabe K, Saito R, Miyauchi E, Nagashima H, Nakamura A, Sugawara S, Tanaka N, Terasaki H, Fukuhara T, Maemondo M.: Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation. Cancers 2023 Aug 24;15(17):4231 doi:10.3390/cancers15174231

 

このページの先頭へ

 

2022年

  1. Tsukita Y, Inoue A. First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study. Jpn J Clin Oncol. 2022 May;52:405-410.
  2. Yamamoto T, Tsukita Y, Katagiri Y, Matsushita H, Umezawa R, Ishikawa Y, Takahashi N, Suzuki Y, Takeda K, Miyauchi E, Saito R, Katsuta Y, Kadoya N, Jingu K. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice. BMC Cancer. 2022 Apr 4;22(1):364.
  3. Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E, Tsuchiya-Kawano Y, Yanagitani N, Nishio M. Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02). Thorac Cancer. 2022 May;13(10):1471-1478.
  4. Mimori T, Shukuya T, Ko R, Okuma Y, Koizumi T, Imai H, Takiguchi Y, Miyauchi E, Kagamu H, Sugiyama T, Azuma K, Namba Y, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Kobayashi K, Takahashi K. Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study. Cancers (Basel). 2022 Jan 11;14(2):331.
  5. Fujimoto D, Akamatsu H, Morimoto T, Wakuda K, Sato Y, Kawa Y, Yokoyama T, Tamiya M, Hiraoka R, Shingu N, Ikeda H, Tamiya A, Kanazu M, Miyauchi E, Miura S, Yanai M, Yomota M, Morinaga R, Yokoi T, Hata A, Suzuki H, Matsumoto H, Sakata S, Furuya N, Harutani Y, Nakachi I, Otsuki A, Uematsu S, Hara S, Yokoo K, Sugimoto T, Yamamoto N. Histologic transformation of epidermal growth factor receptor-mutated lung cancer. Eur J Cancer. 2022 May;166:41-50.
  6. Murakami K, Tamada T, Saigusa D, Miyauchi E, Nara M, Ichinose M, Kurano M, Yatomi Y, Sugiura H. Urine autotaxin levels reflect the disease activity of sarcoidosis. Sci Rep. 2022 Mar 14;12(1):4372. doi: 10.1038/s41598-022-08388-6. PMID: 35288647; PMCID: PMC8921313.
  7. Tsubata Y, Hotta T, Hamai K, Furuya N, Yokoyama T, Saito R, Nakamura A, Masuda T, Hamaguchi M, Kuyama S, Honda R, Senoo T, Nakanishi M, Yamasaki M, Ishikawa N, Fujitaka K, Kubota T, Kobayashi K, Isobe T. A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study. J Hematol Oncol. 2022 Apr 4;15(1):40.
  8. Kazama I, Sato Y, Tamada T. ：Pyridoxine synergistically potentiates mast cell-stabilizing property of ascorbic acid. Cell Physiol Biochem. 56:282-292,2022. doi: 10.33594/000000534.
  9. Koarai A, Yamada M, Ichikawa T, Fujino N, Kawayama T, Sugiura H: Triple versus LAMA/LABA combination therapy for Japanese patients with COPD: A systematic review and meta-analysis. Respir Investig.2022 Jan;60(1):90-98　 doi:10.1016/j.resinv.2021.04.007.
  10. Liu L, Yamamoto A, Yamaguchi M, Taniguchi I, Nomura N, Nakakuki M,　Kozawa Y, FukuyasuT, Higuchi M, Niwa E, Tamada T, Ishiguro H. Bicarbonate transport of airway surface epithelia in luminally perfused mice bronchioles. J Physiol Sci. 2022 Feb 23;72(1):4. doi: 10.1186/s12576-022-00828-2.
  11. Okutomo K. Fujino N, Yamada M, Saito T,Ono Y,Okada Y, Ichinose M, Sugiura H:Increased 　LHX9 expression in alveolar epitherial type 2 cells of patients with chronic obstructive pulmonary disease. Respir Investig. 2022 Jan ;60(1):119-128.
  12. Itakura K, Fujino N, Kamide Y, Saito I, Yamada M, Okutomo K, Tsukita Y, Saito T, Ichikawa T, Numakura T, Kyogoku Y, Aizawa H, Ono Y, Matsumoto S, Hussell T, Taniguchi M, Ichinose M, Sugiura H. ：Decreased expression of airway epithelial Axl is associated with eosinophilic inflammation in severe asthma.　Allergol Int. 2022 Jul;71(3):383-394. doi: 10.1016/j.alit.2022.02.010. Epub 2022 Apr 20.PMID: 35459569
  13. Kazama I, Kuwana R, Muto M, Nagano A, Fujimura R, Asada A, Tamada T, Shimoyama M. Subepicardial burn injuries in bullfrog heart induce electrocardiogram changes mimicking inferior wall myocardial infarction. J Vet Med Sci. 2022 Jul 8. doi: 10.1292/jvms.22-0243.
  14. Kawachi H, Tamiya M, Taniguchi Y, Yokoyama T, Yokoe S, Oya Y, Imaji M, Okabe F, Kanazu M, Sakata Y, Uematsu S, Tanaka S, Arai D, Saito G, Kobe H, Miyauchi E, Okada A, Hara S, Kumagai T.： Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. JTO Clin Res Rep. 2022 Jun 3;3(7):100355. doi: 10.1016/j.jtocrr.2022.100355.
  15. Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, Harada T, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR. J Clin Oncol. 2022 Nov 1;40(31):3587-3592. doi: 10.1200/JCO.21.02911.
  16. Murakami K,Sano H, Tode N, Tsukita Y, Sato K, Narita D, Kimura N, Matsumoto M, Ono Y, Iwasaki C, Sugiyama H, Suzuki M, Kakuto S, Konno S, Kanamori H, Baba H, Oshima K, Takei K, Tokuda K, Tamada T, Sugiura H：Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy. BMJ Open Resp Res. 2022;9:e001332.doi:10.1136/bmjresp-2022-001332
  17. Numakura T, Murakami K, Tamada T, Yamaguchi C, Inoue C, Ohkouchi S, Tode N, Sano H, Aizawa H, Sato K, Mitsune A, Kurosawa H, Nakazawa T, Sugiura H. ：A Novel Development of Sarcoidosis following COVID-19 Vaccination and a Literature Review. Intern Med. 2022 Oct 15;61(20):3101-3106.doi: 10.2169/internalmedicine.0104-22.
  18. Namkoong H, Edahiro R, Takano T, Murakami K, Yamada M, Sugiura H, Sano H, Matsumoto M, Kimura N, Ono Y, Fukunaga K, Okada Y, et al：DOCK2 is involved in the host genetic and biology of sever COVID-19.Nature 2022;609:754-760 doi:10.1038/s41586-022-05163-5
  19. Ohkouchi S, Kanehira M, Saigusa D, Ono M, Tazawa R, Terunuma H, Hirano T, Numakura T, Notsuda H, Inoue C, Saito-Koyama R, Tabata M, Irokawa T, Ogawa H, Kurosawa H, Okada Y.：Metabolic and Epigenetic Regulation of SMAD7 by STC1 Ameliorates Lung Fibrosis. Am J Respir Cell Mol Biol. 2022 Sep;67(3):320-333. doi: 10.1165/rcmb.2021　0445OC.PMID: 35696344
  20. Sano H, Murakami K, Yokoyama H, Suzuki C, Iwasaki Y, Kodama E, Sugiura H：COVID-19 in a hairy cell leukemia patient: a Rare Case report. Tohoku Exp Med. 2022 Aug 10;258(1)63-68. Doi10.1620/tjem.2022. J058
  21. Shirota H, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Tada H, Shimada M, Niihori T, Aoki Y, Sugiyama I, Kawamura M, Yasuda J, Suzuki S, Iwaya T, Saito M, Saito T, Shibata H, Furukawa T, Ishioka C. Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study. Cancer Med. 2022 Oct 17. doi: 10.1002/cam4.5349. Epub ahead of print. PMID: 36251535.
  22. Takeda Y, Kusaba Y, Tsukita Y, Uemura Y, Miyauti E, Yamamoto T, Mayahara H, Hata A, Nakayama H, Tanaka S, Uchida J, Usui K Toyoda T, Tamiya M, Morimoto M,Oya Y, Kodaira T, Jingu K, Sugiura H：The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage Ⅲ non- smaii cell lung cancer: A multicenter retrospective cohort study. Clin Transl Radiat Oncol. 2022 aug23：37：57-63. Doi:10.1016/j.ctro.2022.08.010
  23. Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Ohizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. ：Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). Int J Clin Oncol. 2022 Jan;27(1):112-120. doi: 10.1007/s10147-021-02043-2. Epub 2021 Oct 13. Erratum in: Int J Clin Oncol. 2022 Apr;27(4):823-824.
  24. Yamamoto T, Katagiri Y, Tsukita Y, Matsushita H, Umezawa R, Katsuta Y, Kadoya N, Takahash Ni, Suzuki Y, Takeda K, Kishida K, Omata S, Miyauchi E, Saito R, Keiichi Jingu K.: Stereotactic Radiosurgery for Lung Cancer with a Risk-Adapted Strategy Using the Volumetric Modulated Arc Therapy Technique: A Single Arm Phase II Study. Cancers (Basel). 2022 Aug 18;14(16):3993.
  25. Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D.：Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer: A Real-World Setting. Chest. 2022 Jun 1;S0012-3692(22)01068-6.
  26. Wang QS,Edahiro R,Namkoong H,Murakami K, Yamada M, Sugiura H, Sano H, Matsumoto M, Kimura N, Ono Y,Fukunaga K, Okada Y.et al：The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force. Nat Commun. 2022 Aug 22;13(1):4830. Doi:10.1038/s41467-022-32276-2.
  27. Watanabe Y, Sano H, Konno S, Kamioka Y, Hariu M, Takano K, Yamada M, Seki M. Sinobronchial Syndrome Patients with Suspected Non-Tuberculous Mycobacterium Infection Exacerbated by Exophiala dermatitidis Infection. Infect Drug Resist 2022; 15: 1135-1141.
  28. Takase M, Yamada M, Nakamura T, Nakaya N, Kogure M, Hatanaka R, Nakaya K, Kanno I, Nochioka K, Tsuchiya N, Hirata T, Hamanaka Y, Sugawara J, Kobayashi T, Fuse N, Uruno A, Kodama EN, Kuriyama S, Tsuji I, Hozawa A.：The Association of Lung Function and Carotid Intima-Media Thickness in a Japanese Population: The Tohoku Medical Megabank Community-Based Cohort Study．J Atheroscler Thromb. 2022 Nov 4. doi: 10.5551/jat.63826. Online ahead of print

 

このページの先頭へ

 

2021年

  1. Abe K, Kanehira M, Ohkouchi S, Kumata S, Suzuki Y, Oishi H, Noda M, Sakurada A, Miyauchi E, Fujiwara T, Harigae H, Okada Y. Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer. Cancer Med. 2021 May;10(9):3085-3100.
  2. Aritake H, Tamada T, Murakami K, Gamo S, Nara M, Kazama I, Ichinose M, Sugiura H. Effects of indacaterol on the LPS-evoked changes in fluid secretion rate and pH in swine tracheal membrane. Pflugers Arch. 2021 May 24. doi: 10.1007/s00424-021-02560-z. Online ahead of print. PMID: 34031755
  3. Ebina-Shibuya R, West EE, Spolski R, Li P, Oh J, Kazemian M, Gromer D, Swanson P, Du N, McGavern DB, Leonard WJ. Thymic stromal lymphopoietin limits primary and recall CD8+ T-cell anti-viral responses. eLife. 2021;10:e61912 DOI: 10.7554/eLife.61912
  4. Fujino N, Sugiura H. ACO (Asthma–COPD Overlap) Is Independent from COPD, a Case in Favor: A Systematic Review. Diagnostics. 2021;11(5):859 - 859.
  5. Hizawa N, Fukunaga K, Sugiura H, Nakano Y, Kato M, Sugiyama Y, Hanazawa T, Kaise T, Tal-Singer R, Jones PW, Barnes N, Compton C, Ishii T. A Prospective Cohort Study to Assess Obstructive Respiratory Disease Phenotypes and Endotypes in Japan: The TRAIT Study Design. Int J Chron Obstruct Pulmon Dis. 2021 Jun 18;16:1813-1822.
  6. Ishii M, Horita N, Takeuchi M, Matsumoto H, Ebina-Shibuya R, Hara Y, Kobayashi N, Mizuki N, Kaneko T. Inhaled Corticosteroid and Secondary Glaucoma: A Meta-analysis of 18 Studies. Allergy Asthma Immunol Res. 2021 May;13(3):435-449.
  7. Koarai A, Yamada M, Ichikawa T, Fujino N, Kawayama T, Sugiura H. Triple versus LAMA/LABA combination therapy for Japanese patients with COPD: A systematic review and meta-analysis. Respir Investig. 2021 Jun 5:S2212-5345(21)00077-0.
  8. Matsumoto H, Horita N, Ito K, Ebina-Shibuya R, Hara Y, Kobayashi N, Kaneko T. Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials. Transl Lung Cancer Res. 2021 May;10(5):2278-2289.
  9. Matsunaga K, Kuwahira I, Hanaoka M, Saito J, Tsuburai T, Fukunaga K, Matsumoto H, Sugiura H, Ichinose M; Japanese Respiratory Society Assembly on Pulmonary Physiology. An official JRS statement: The principles of fractional exhaled nitric oxide (FeNO) measurement and interpretation of the results in clinical practice. Respir Investig. 2021;59(1):34-52. PMID: 32773326
  10. Mitsune A, Yamada M, Fujino N, Numakura T, Ichikawa T, Suzuki A, Matsumoto S, Mitsuhashi Y, Itakura K, Makiguchi T, Koarai A, Tamada T, Endo S, Takai T, Okada Y, Suzuki S, Ichinose M, Sugiura H. Upregulation of leukocyte immunoglobulin-like receptor B4 on interstitial macrophages in COPD; their possible protective role against emphysema formation. Respir Res. 2021 Aug 23;22(1):232.
  11. Miyauchi E, Tanaka H, Nakamura A, Harada T, Nakagawa T, Morita M, Jingu D, Kuda T, Gamou S, Saito R, Inoue A. Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer: NJLCG1402. Thorac Cancer. 2021 Nov;12(21):2886-2893.
  12. Mukae H, Kaneko T, Obase Y, Shinkai M, Katsunuma T, Takeyama K, Terada J, Niimi A, Matsuse H, Yatera K, Yamamoto Y, Azuma A, Arakawa H, Iwanaga T, Ogawa H, Kurahashi K, Gon Y, Sakamoto H, Shibata Y, Tamada T, Nishioka Y, Haranaga S, Fujieda S, Miyashita N, Mochizuki H, Yokoyama A, Yoshihara S, Tamaoki J; JRS guidelines committee for the management of cough and sputum. The Japanese respiratory society guidelines for the management of cough and sputum (digest edition). Respir Investig. 2021 May;59(3):270-290. doi: 10.1016/j.resinv.2021.01.007. Epub 2021 Feb 26.
  13. Muro S, Sugiura H, Darken P, Dorinsky P. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts. Respir Res. 2021 Jun 28;22(1):187.
  14. Nishino K, Fujiwara Y, Ohe Y, Saito R, Miyauchi E, Kobayashi T, Nakai Y, Takahashi T, Shibata T, Hamaguchi T, Kikuchi K, Yamazaki N, Fukuda H, Nozawa K, Kiyohara Y. Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). Support Care Cancer. 2021 May;29(5):2327-2334.
  15. Saito T, Ichikawa T, Numakura T, Yamada M, Koarai A, Fujino N, Murakami K, Yamanaka S, Sasaki Y, Kyogoku Y, Itakura K, Sano H, Takita K, Tanaka R, Tamada T, Ichinose M, Sugiura H. PGC-1α regulates airway epithelial barrier dysfunction induced by house dust mite. Respir Res. 2021;22(1):63. PMID: 33607992
  16. Saito G, Oya Y, Taniguchi Y, Kawachi H, Daichi F, Matsumoto H, Iwasawa S, Suzuki H, Niitsu T, Miyauchi E, Yokoi T, Yokoyama T, Uenami T, Sakata Y, Arai D, Okada A, Nagata K, Teraoka S, Kokubo M. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON). Lung Cancer. 2021 Nov;161:86-93.
  17. Saito N, Kikuchi A, Yamaya M, Deng X, Sugawara M, Takayama S, Nagatomi R, Ishii T. Kakkonto inhibits cytokine production induced by rhinovirus infection in primary cultures of human nasal epithelial cells. Front Pharmacol. 2021 Aug 31;12:687818. doi: 10.3389/fphar.2021.687818.
  18. Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer. 2021 Dec;159:144-153.
  19. Sato K, Hayashi H, Shimotai Y, Yamaya M, Hongo S, Kawakami K, Matsuzaki Y, Nishimura H. TMPRSS2 activates hemagglutinin-esterase glycoprotein of influenza C virus. J Virol. 2021 Aug 18; JV0129621. doi: 10.1128/JVI.01296-21.
  20. Tamada T, Nara M, Murakami K, Gamo S, Aritake H, Shimizu M, Kazama I, Ichinose M, Sugiura H. The Clinical Features of Patients with Sarcoidosis and Malignant Diseases in Japan. Intern Med. 2021;60(2):209-216. doi: 10.2169/internalmedicine.5441-20. Epub 2021 Jan 15. PMID: 33456025
  21. Tanaka R, Koarai A, Yamada M, Fujino N, Ichikawa T, Numakura T, Onodera K, Kyogoku Y, Tamada T, Miura M, Minakata Y, Ichinose M, Sugiura H. Longitudinal Relationship Between Growth Differentiation Factor 11 and Physical Activity in Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2021;16:999-1006. PMID: 33456025
  22. Tanaka H, Ho Lee,Morita A, Namkoong Ho, Chubachi S, Kamata H, Ishii M, Hasegawa N, Harada N, Ueda T, Ishiguro T, Arimura K, Saito F, Yoshiyama T, Nakano Y, Mutoh Y, Murakami K, Okada Y, Koike R, Kitagawa Y, Tokunaga K, Kimura A, Imoto S, Miyano S, Ogawa S, Kanai T, Fukunaga K, The Japan COVIC-19 Task Force：Clinical Characteristics of Patients with Coronavirus Disease (COVID-19): Preliminary Baseline Report of Japan COVID-19 Task Force, a Nationwide Consortium to Investigate Host Genetics of COVID-19. Int J Infect Dis. 2021 Dec;113:74-81. doi: 10.1016/j.ijid.2021.09.070. Epub 2021 Sep 30.
  23. Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Ohizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). Int J Clin Oncol. 2021 Oct 13.
  24. Tsubata Y, Shinomiya S, Inoue K, Ishikawa N, Saito R, Nakashima K, Hotta K, Hamada A, Nagashima F, Ando Y, Morita S, Kobayashi K, Isobe T. Protocol for a multi-site, cluster-randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non-small-cell lung cancer: the ENSURE-GA study. BMC Geriatr. 2021 Jan 22;21(1):74.
  25. Tsukita Y, Yamamoto T, Mayahara H, Hata A, Takeda Y, Nakayama H, Tanaka S, Uchida J, Usui K, Toyoda T, Tamiya M, Morimoto M, Oya Y, Kodaira T, Miyauchi E, Jingu K, Sugiura H. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: a multi-center retrospective study. Radiother Oncol. 2021;S0167-8140(21)06254-X. PMID: 34023330
  26. Watanabe K, Toi Y, Nakamura A, Chiba R, Akiyama M, Sakakibara-Konishi J, Tanaka H, Yoshimura N, Miyauchi E, Nakagawa T, Igusa R, Minemura H, Mori Y, Fujimoto K, Matsushita H, Takahashi F, Fukuhara T, Inoue A, Sugawara S, Maemondo M; North Japan Lung Cancer Study Group, Sendai, Japan. Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001. Transl Lung Cancer Res. 2021 Feb;10(2):712-722.
  27. Yamada M. ：Extracellular vesicles: Their emerging roles in the pathogenesis of respiratory diseases. Respir Investig. 2021; 59: 302-311.　DOI：10.1016/j.resinv.2021.02.006
  28. Yamada M, Motoike IN, Kojima K, Fuse N, Hozawa A, Kuriyama S, Katsuoka F, Tadaka S, Shirota M, Sakurai M, Nakamura T, Hamanaka Y, Suzuki K, Sugawara J, Ogishima S, Uruno A, Kodama EN, Fujino N, Numakura T, Ichikawa T, Mitsune A, Ohe T, Kinoshita K, Ichinose M, Sugiura H, Yamamoto M. Genetic loci for lung function in Japanese adults with adjustment for exhaled nitric oxide levels as airway inflammation indicator. Commun Biol. 2021 Nov 15;4(1):1288.
  29. Yamamoto G, Asahina H, Honjo O, Sumi T, Nakamura A, Ito K, Kikuchi H, Hommura F, Honda R, Yokoo K, Fujita Y, Oizumi S, Morita R, Ikezawa Y, Tanaka H, Kimura N, Sasaki T, Sukoh N, Takashina T, Harada T, Dosaka-Akita H, Isobe H; Hokkaido Lung Cancer Clinical Study Group Trial. First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002). Sci Rep. 2021 Nov 30;11(1):23140.

 

このページの先頭へ

 

2020年

  1. Tsukita Y, Inoue A, Sugawara S, Kuyama S, Nakagawa T, Harada D, Tanaka H, Watanabe K, Mori Y, Harada T, Hino T, Fujii M, Ichinose M. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan Lung Cancer Study Group Trial 1203 Lung Cancer. 2020;139:89-93
  2. Tanno A, Fujino N, Yamada M, Sugiura H, Hirano T, Tanaka R, Sano H, Suzuki S, Okada Y, Ichinose M. Decreased expression of a phagocytic receptor Siglec-1 on alveolar macrophages in chronic obstructive pulmonary disease Respiratory Res 2020:21 doi.org/10.1186/s12931-020-1297-2
  3. Makiguchi T, Koarai A, Inoue C, Aoyama Y, Hirano T, Ohe T, Ichikawa T, Shishikura Y, Komuro H, Tsukita Y, Tode N, Numakura T, Saito T, Sato T, Mitsuhashi Y, Tamada T, Sugiura H, Ichinose M. A case of localized tracheobronchial relapsing polychondritis with positive matrilin-1 staining BMC Rheumatology 2020 4:1. doi: https://doi.org/10.1186/s41927-019-0103-6
  4. Akira Koarai, Hisatoshi Sugiura, Mitsuhiro Yamada, Tomohiro Ichikawa, Naoya Fujino, Tomotaka Kawayama and Masakazu Ichinose. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. BMC Pulmonary Medicine 2020; 20:111
  5. Tsukita Y, Miyauchi E, Fukudo M, Sasaki T, Ichinose M：Immunotherapy-related Hepatitis and Thrombocytopaenia Induced by the Very Low Dose of Only 90 Mg of Atezolizumab. Eur J Cancer 2020; 133: 22-24.
  6. Saito R, Miki Y, Abe T, Miyauchi E, Abe J, Nanamiya R, Inoue C, Sato I, Sasano H. 11β hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma. Br J Cancer 2020. doi: 10.1038/s41416-020-0837-3.
  7. Sano H, Murakami K, Tamada T, Ichinose M. Mycobacterium Abscessus Infection Limited to the Main Bronchus. Intern Med 2020. doi: 10.2169/internalmedicine.4883-20.
  8. Abe N, Toyama H, Ejima Y, Saito K, Tamada T, Yamauchi M, Kazama I. α1-Adrenergic Receptor Blockade by Prazosin Synergistically Stabilizes Rat Peritoneal Mast Cells. Biomed Res Int. 2020 May 12;2020:3214186. doi: 10.1155/2020/3214186. eCollection 2020.
  9. Yamaya M, Kawakami G, Momma H, Yamada A, Itoh J, Ichinose M. Effects of Nutritional Treatment on the Frequency of Pneumonia in Bedridden Patients Receiving Oral Care. Intern Med 2020; 59: 181-192.
  10. Yamaya M, Usami O, Nakayama S, Tode N, Yamada A, Ito S, Omata F, Momma H, Funakubo M, Ichinose M. Malnutrition, Airflow Limitation and Severe Emphysema are Risks for Exacerbation of Chronic Obstructive Pulmonary Disease in Japanese Subjects: A Retrospective Single-Center Study. Int J Chron Obstruct Pulmon Dis 2020; 15: 857-868.
  11. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, Shimotai Y, Momma H, Ichinose M, Kawase T. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig 2020; 58: 155-168.

 

このページの先頭へ

 

2019年

  1. Kyogoku Y, Sugiura H, Ichikawa T, Numakura T, Koarai A, Yamada M, Fujino N, Tojo Y, Onodera K, Tanaka R, Sato K, Sano H, Yamanaka S, Itakura K, Mitsune A, Tamada T, Akaike T, Ichinose M.： Nitrosative stress in patients with asthma-chronic obstructive pulmonary disease overlap．J Allergy Clin Immunol. 2019 May 9. pii: S0091-6749(19)30609-8. doi: 10.1016/j.jaci.2019.04.023.
  2. Matsuda T, Miyauchi E, Hsu YW, Nagayama S, Kiyotani K, Zewde M, Park JH, Kato T, Harada M, Matsui S, Ueno M, Fukuda K, Suzuki N, Hazama S, Nagano H, Takeuchi H, Vigneswaran WT, Kitagawa Y, Nakamura Y.：TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. Oncoimmunology. 2019 Mar 22;8(6):e1588085.
  3. Miyauchi E, Matsuda T, Kiyotani K, Low SK, Hsu YW, Tsukita Y, Ichinose M, Sakurada A, Okada Y, Saito R, Nakamura Y.：Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations. Cancer Sci. 2019 Mar;110(3):867-874. doi: 10.1111/cas.13919. Epub 2019 Feb 16.
  4. Tsukita Y, Fujino N, Miyauchi E, Saito R,Fujishima F,Itakura K,Kyogoku Y, Okutomo K, Yamada M,Okazaki T, Sugiura H< Inoue A, Okada Y,Ichinose M : Axl kinase drivers immune checkpoint and chemokine signaling pathwaus in lung adenocarcinomas. Molecular Cancer 2019:18(1):24.doi.org/10.1186/s12943-019-0953-y
  5. Ichikawa T, Panariti A, Audusseau S, Mogas AK, Olivenstein R, Chakir J, Laviolette M, Allakhverdi Z, Al Heialy S, Martin JG, Hamid Q：Effect of bronchial thermoplasty on structural changes and inflammatory mediators in the airways of subjects with severe asthma.　Respiratory Medicine. 2019 Apr;150:165-172. doi: 10.1016/j.rmed.2019.03.005.
  6. Hirano T, Matsunaga K, Hamada K, Uehara S, Suetake R, Yamaji Y, Oishi K, Asami M, Edakuni N, Ogawa H, Ichinose M. ：Combination of assist use of short-acting beta-2 agonists inhalation and guidance based on patient-specific restrictions in daily behavior: Impact on physical activity of Japanese patients with chronic obstructive pulmonary disease. Respir Investig. 2019 Jan 3. pii: S2212-5345(18)30108-4.
  7. Fujino N, Oliver J. Brand1, David J. Morgan1, Fujimori T, Aleksander M. Grabiec、 Christopher P. Jagger1,Rose A. Maciewicz, Yamada M, Itakura K, Sugiura H, Ichinose M, Tracy Hussell：Sensing of apoptotic cells through Axl causes lung basal cell proliferation in inflammatory diseases. Journal of Experimental Medicine, doi.org/10.1084/jem.20171978
  8. Hayakawa S, Kawamura M, Sato T, Hirano T, Kikuchi T, Watanabe A, Fujimura S:An α-Lipoic acid derivative, and anti-ROS agent, prevents the acquisition of multi-drug resistance in clinical isolates of Pseudomonas aeruginosa. J Infect Chemother. 2019 Jan ; 5(1) : 28-33 doi: 10.1016/j.jiac.2018.10.003.
  9. Ichinose M, Fukushima Y, Inoue Y, Hataji O, Faguson TG, Rabe FB, Hayashi N, Okada H,Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Reisner C, Dorinsky P. Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered DoseInhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD. Int J COPD 2019:14 2993–3002
  10. Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson TG, Rabe FB, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAangelis K, Aurivillius M, Dorinsky P, Reisner C. Efficacy and Safety of Budesonide/Glycopyrrolate/ Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study. Int J COPD 2019:14 2979–2991
  11. Ishizawa K, Yamanaka M, Saiki Y, Miyauchi E, Fukushige S, Akaishi T, Asao A, Mimori T, Saito R, Tojo Y, Yamashita R, Abe M, Sakurada A, Pham NA, Li M, Okada Y1, Ishii T, Ishii N, Kobayashi S, Nagasaki M, Ichinose M, Tsao MS, Horii A. CD45+CD326+ Cells are predictive of poor prognosis in Non-Small Cell Lung Cancer patients. Clin Cancer Res. 2019 Aug 5. pii: clincanres.0545.2019. doi: 10.1158/1078-0432.CCR-19-0545.
  12. Machida K, Kawayama T, Kinoshita M, Ichinose M, Tsuada T, Takata S, Koto H, Yoshida M, Ashihara Y, Kawashima M, Suna H, Inoue H. Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease:A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase Ⅱ Trial. Int J COPD. 2019:14 2175-2184
  13. Minakata Y,Motegi T,Ueki J,Gon Y,Nakamura S,Anzai Tatsuhiko,Hirata K,Ichinose M.：Effect of tiotropium/olodaterol on sedentary and anaylsis of the VESUTO® study. Int J COPD. 2019:14 :1789-1801.
  14. Nakata, K, Sugi, T, Kuroda K, Yoshizawa K, Takada T, Tazawa R, Ueda T, Aoki A, Abe M, Tatsumi K, Eda, R, Kondoh S, Morimoto K, TanakaT ,Yamaguchi E, Takahashi A, Oda M, Ishii H, Izumi S,Sugiyama H,Nakagawa A,Tomii K, Suzuki M, Konno S, Ohkochi S, Hirano T, Handa T, Hirai T, Inoue Y, Arai T ,Asakawa K, Sakagami T, Tanaka T, Mikami, A, Kitamura N: Validation of a New Serum Granulocyte/Macrophage Colony-Stimulating Factor Autoantibody Testing Kit. ERJ Open Res. 2020 Jan; 6(1): 00259-2019. doi: 10.1183/23120541.00259-2019.
  15. Suzuki T, Ota C, Fujino N, Tando Y, Suzuki S, Yamada M, Kondo T, Okada Y, Kubo H. ：Improving the viability of tissue-resident stem cells using an organ-preservation solution. FEBS Open Bio 2019; 9: 2093-2104.
  16. Takei Y, Yamada M, Saito K, Kameyama Y, Sugiura H, Makiguchi T, Fujino N, Koarai A, Toyama H, Saito K, Ejima Y, Kawazoe Y, Kudo D, Kushimoto S, Yamauchi M, Ichinose M. ： Increase in circulating ACE-positive endothelial microparticles during acute lung injury. Eur Respir J 2019. Jul 18. pii: 1801188. doi: 10.1183/13993003.01188-2018

 

このページの先頭へ

 

2018年

  1. Yamada M, Ichinose M. The cholinergic anti-inflammatory pathway: an innovative treatment strategy for respiratory diseases and their comorbidities. Curr Opin Pharmacol 2018 Jan 11; 40:18-25.
  2. Aizawa H, Koarai A, Shishikura Y, Yanagisawa S, Yamaya M, Sugiura H, Numakura T, Yamada M, Ichikawa T, Fujino N, Noda M, Okada Y, Ichinose M. Oxidative stress enhances the expression of IL-33 in human airway epithelial cells. Respir Res　2018 Mar 27; 19(1):52.
  3. Yamada E, Himori N, Kunikata H, Omodaka K, Ogawa H, Ichinose M, Nakazawa T. The relationship between increased oxidative stress and visual field defect progression in glaucoma patients with sleep apnoea syndrome. Acta Ophthalmol　2018 Mar 2.
  4. Mitsune A, Yanagisawa S, Fukuhara T, Miyauchi E, Morita M, Ono M, Tojo Y, Ichinose M. Relapsed Myasthenia Gravis after Nivolumab Treatment. Intern Med　2018 Feb 9.
  5. Yanagisawa S, Ichinose M. Definition and diagnosis of asthma-COPD overlap (ACO). Allergol Int　2018 Feb 9. pii: S1323-8930(18)30002-9.
  6. Koarai A, Ichinose M. Possible involvement of acetylcholine-mediated inflammation in airway diseases. Allergol Int　2018 Mar 28. pii: S1323-8930(18)30013-3.
  7. Yamaya M, Yoshigoe H, Murakami K, Nakayama S, Ichinose M. Asthma Exacerbation Caused by Bacterial Infection in Two Elderly Patients. J Infect Dis Preve Med 2018 6: 176.
  8. Tanaka R, Sugiura H, Yamada M, Ichikawa T, Koarai A, Fujino N, Yanagisawa S, Onodera K, Numakura T, Sato K, Kyogoku Y, Sano H, Yamanaka S, Okazaki T, Tamada T, Miura M, Takahashi T, Ichinose M. Physical inactivity is associated with decreased growth differentiation factor 11 in chronic obstructive pulmonary disease. Int J COPD 2018 Apr 24; 13:1333-1342.
  9. Ichinose M, Minakata Y, Motegi T, Ueki J, Gon Y, Seki T, Anzai T, Nakamura S, Hirata K. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity. Int J COPD 2018 May 1; 13:1407-1419.
  10. Hirano T, Ohkouchi S, Tode N, Kobayashi M, Ono M, Sato T, Mitsuishi Y, Watanabe A, Tabata M, Irokawa T, Ogawa H, Sugiura H, Kikuchi T, Akasaka K, Tazawa R, Inoue Y, Nakata K, Kurosawa H, Ichinose M. Peripheral alveolar nitric oxide concentration reflects alveolar inflammation in autoimmune pulmonary alveolar proteinosis. ERJ Open Res. 2018 Mar 23; 4(1).
  11. Kamata S, Fujino N, Yamada E, Grime K, Suzuki S, Ota C, Tando Y, OkadaY, Sakurada A, Noda M, Matsuda Y, Sugiura H, Ichinose M. Expression of cytochrome P450 mRNAs in Type II alveolar cells from subjects with chronic obstructive pulmonary disease.Pharmacol Res Perspect.2018; e00405.
  12. Komatsu R, Okazaki T, Ebihara S, Kobayashi M, Tsukita Y, Nihei M, Sugiura H, Niu K, Ebihara T, Ichinose M. Aspiration pneumonia induces muscle atrophy in the respiratory, skeletal, and swallowing systems. JCSM 2018；doi:10.1002/jcsm.12297.
  13. Hirano T, Numakura T, Moriyama H, Saito R, Shishikura Y, Sugiura H, Ichinose M. The first case of multiple pulmonary granulomas with amyloid deposition in a dental technician; a rare manifestation as an occupational lung disease. BMC Pulm Med 2018 May 22;18(1):77. doi: 10.1186/s12890-018-0654-0.
  14. Hirano T, Fujino N, Takase K, Ota H, Tanaka R, Saito R, Suzuki A, Okutomo K, Sato T, Kageyama S, Tamada T, Sugiura H, Ichinose M. Pulmonary Lymphatic Perfusion Syndrome.Am J Respir Crit Care Med. 2018 Sep 21.
  15. Tsukita Y, Okazaki T, Ebihara S, Komatsu R, Nihei M, Kobayashi M, Hirano T, Sugiura H, Tamada T, Tanaka N, Sato Y, Yagita H, Ichinose M. Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5. Oncoimmunology. 2018 Nov 13;8(2)
  16. Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018; 6: 747-758.
  17. Gamo S, Tamada T, Murakami K, Muramatsu S, Aritake H, Nara M, Kazama I, Okazaki T, Sugiura H, Ichinose M. TLR7 agonist attenuates acetylcholine-induced, Ca2+ -dependent ionic currents in swine tracheal submucosal gland cells. Exp Physiol. 103:1543-1559, 2018. doi: 10.1113/EP087221.

 

このページの先頭へ

 

2017年

  1. Bai C, Ichinose M, Lee SH, Lee KH, Jöns O, Bothner U, Zhao Y, Buhl R: Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease. International Journal of COPD 2017:12 3329–3339
  2. Ebina-Shibuya R, Matsumoto M, Kuwahara M, Kyoung-Jin Jang, Sugai M, Ito Y, Funayama R, Nakayama K, Sato Y, Ishii N, Okamura Y, Kinoshita K, Kometani K, Kurosaki T, Muto A, Ichinose M,Yamashita M,Igarashi K: Inflammatory responses induce an identity crisis of alveolar macrophages leading to pulmonary alveolar proteinases. J Biol Chem. 2017Nov 3;292(44):18098-18112.
  3. Hirano T, Yamada M, Sato K, Murakami K, Tamai T, Mitsuhashi Y, Tamada T, Sugiura H, Sato N, Saito R, Tominaga J, Watanabe A, Ichinose M:Invasive pulmonary mucormycosis: rare presentation with pulmonary eosinophilia. BMC Pulm Med. 2017;17(1):76.
  4. Hirano T, Yamada M, Ichinose M：Chronic Cholestasis with Dilation of Intrahepatic Bile Duct Related to Administration of Ceritinib. J Thorac Oncol. 2017;12(8):e123-e125.
  5. Miyauchi E, Inoue A, Usui K, Sugawara S, Maemondo M, Saito H, Fujita Y, Kato T, Suzuki T, Harada T, Watanabe H, Nakagawa T, Ichinose M. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301. Oncologist. 2017 May 19. 2017 Jun;22(6):640-e59
  6. Ichinose M, Kato M, Takizawa A, Sakamoto W, Grönke L, Tetzlaff K, Fukuchi Y.Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease. Respir Investig. 2017;55(2):121-129
  7. Ichinose M, Sugiura H, Nagase H, Yamaguchi M, Inoue H, Sagara H, Tamaoki J, Tohda Y, Munakata M, Yamauchi K, Ohta K; Japanese Society of Allergology. Japanese guidelines for adult asthma 2017.Allergol Int. 2017 ;66(2):163-189
  8. Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T, Takizawa A, Grönke L, Hirata K. Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease. Adv Ther. 2017 ;34(7):1622-1635
  9. Ichinose M :ASTHMA PREVENTION AND MANAGEMENT GUIDELINE 2015.Arerugi. 2017;66(2):77-81
  10. Inoue H, Nagase T, Morita S, Yoshida A, Jinnai T, Ichinose M: Prevalence and characteristics of asthma–COPD overlap syndrome identified by a stepwise approach. International Journal of COPD 2017;12: 1803-1810
  11. Miyauchi E, Ichinose M, Inoue A. Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease. J Thorac Oncol. 2017 ;12(5):e59-e61.
  12. Numakura T, Sugiura H, Akaike T, Ida T, Fujii S, Koarai A, Yamada M, Onodera K, Hashimoto Y, Tanaka R, Sato K, Shishikura Y, Hirano T, Yanagisawa S, Fujino N, Okazaki T, Tamada T, Hoshikawa Y, Okada Y, Ichinose M： Production of reactive persulfide species in chronic obstructive pulmonary disease. Thorax. 2017Dec;72(12):1074-1083
  13. Ohkouchi S, Akasaka K, Ichiwata T, Hisata S, Iijima H, Takada T, Tsukada H, Nakayama H, Machiya JI, Irokawa T, Ogawa H, Shibata Y, Ichinose M, Ebina M, Nukiwa T, Kurosawa H, Nakata K, Tazawa R:Sequential GM-CSF Inhalation after Whole Lung Lavage for Pulmonary Alveolar Proteinosis: A Report of Five Intractable Cases. Ann Am Thorac Soc. 2017Aug;14(8)：1298-1304.
  14. Onodera K, Sugiura H, Yamada M, Koarai A, Fujino N, Yanagisawa S, Tanaka R, Numakura T, Togo S, Sato K, Kyogoku Y, Hashimoto Y, Okazaki T, Tamada T, Kobayashi S, Yanai M, Miura M, Hoshikawa Y, Okada Y, Suzuki S, Ichinose M：Decrease in an anti-ageing factor, growth differentiation factor 11, in chronic obstructive pulmonary disease. Thorax 2017Oct;72(10)893-904.
  15. Risa Ebina-Shibuya, Matsumoto M, Kuwahara M, Kyoung-Jin Jang, Sugai M, Ito Y, Funayama R, Nakayama K, Sato Y, Ishii N , Okamura Y , KinoshiK, Kometani K , Kurosaki T, Muto A, Ichinose M, Yamashia　M, Igarashi K：Inflammatory responses induce an identity crisis of alveolar macrophages leading to pulmonary alveolar proteinases. J Biol Chem. Nov 3;292(44):18098-18112, 2017
  16. Tamada T, Sugiura H, Takahashi T, Matsunaga K, Kimura K, Katsumata U, Ohta K, Ichinose M: Coexisting COPD in elderly asthma with fixed airflow limitation: assessment by DLco %predicted and HRCT. J asthma. 2017 Aug;54(6):606-615.
  17. Tojo Y, Yanagisawa S, Miyauchi E, Ichinose M：Splenic tuberculosis. Int J Infect Dis 2017 Dec:67 41-42．
  18. Tode N, Kikuchi T, Sakakibara T, Hirano T, Inoue A, Ohkouchi S, Tamada T, Okazaki T, Koarai A, Sugiura H, Niihori T, Aoki Y, Nakayama K, Matsumoto K, Matsubara Y, Yamamoto M, Watanabe A, Nukiwa T, Ichinose M : Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer. Cancer Sci. 2017;108(6):1263-1270.
  19. Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D:Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. International Journal of COPD 2017;19(12):339-349.
  20. Yanagisawa S, Inoue C, Ichinose M: Necrobiotic Pulmonary Nodules of Rheumatoid Arthritis. Am J Med Sci. 2017:354(3):329.
  21. Yanagisawa S, Miyauchi E, Ichinose M:Numb Chin Syndrome: An Ominous Sign of Lung Cancer. J Thorac Oncol. 2017;12(8):e114-e116.
  22. Kitamura N, Seyama K, Inoue Y, Nagai K, Suzuki M, Moriyama H, Takada T, Tazawa R, Hirai T, Mishima M, Hayashida M, Hirose M, Arai T, Sugimoto C, Hattori N, Watanabe K, Tamada T, Akazawa K, Tanaka T, Nakata K. Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study. Pharmacoepidemiol Drug Saf. 26:1182-1189, 2017. doi: 10.1002/pds.4259.

 

このページの先頭へ

 

2016年

  1. Abe K, Sugiura H, Hashimoto Y, Ichikawa T, Koarai A, Yamada M, Numakura T, Onodera K, Tanaka R, Sato K, Yanagisawa S, Okazaki T, Tamada T, Kikuchi T, Ichinose M. Possible role of Krüppel-like factor 5 in the remodeling of small airways and pulmonary vessels in chronic obstructive pulmonary disease. Respir Res. 2016；17：7-20
  2. Fukuchi Y, Tatsumi K, Inoue H, Sakata Y, Shibata K, Miyagishi H, Marukawa Y, Ichinose M. Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study Int J of COPD. 2016; 11: 831-838.
  3. Foo J, Landis SH, Maskell J, Oh YM, van der Molen T, Han MK, Mannino DM, Ichinose M, Punekar Y. Continuing to confront COPD international patient survey: Ecomic impact of COPD in 12 countries. PLoS One. 2016; 11e0152618.
  4. Fukuchi Y, Tatsumi K, Inoue H, Sakata Y, Shibata K, Miyagishi H, Marukawa Y, Ichinose M：Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study. Int J of COPD. 2016; 11: 831-838
  5. Ichinose M. Assessment of the need for nitric oxide measurement in patients with respiratory diseases. Resp Investig.2016; 54: 137-138.
  6. Hashimoto Y, Sugiura H, Togo S, Koarai A, Abe K, Yamada M, Ichikawa T, Kikuchi T, Numakura T, Onodera K, TanakaｚR, Sato K, Yanagisawa S, Okazaki T, Tamada T, Kikuchi T, Hoshikawa Y, Okada Y, Ichinose M. 27-Hydroxycholesterol accelerates cellular senescence in human lung resident cells. Am J Physiol Lung Cell Mol Physiol. 2016;310(11):L1028-41
  7. Hirano T, Yamada M, Igusa R, Tanno A, Nunakura T, Sakamoto K, Kikuchi T, Ichinose M. Two case of endobronchial aspergilloma complicated with primary and metastatic lung cancer: A case report and literature review. Respir Investig. 2016;54(3):211-215
  8. Hirano T, Kikuchi T, Tode N, Santoso A, Yamada M, Mitsuhashi Y, Komatsu R, Kawabe T, Tanimoto T, Ishii N, Tanaka Y, Nishimura H, Nukiwa T, Watanabe A, Ichinose M. OX40 ligand newly expressed on bronchiolar progenitors mediates infection and further exacerbates pneumoria. EMBO Mol Med. 2016; 8: 422-436
  9. Hirano T, Miyauchi E, Inoue A, Igusa R, Chiba S, Sakamoto K, Sugiura H, Kikuchi T, Ichinose M. Two cases of pseudo-achalasia with lung cancer: Case report and short literature review. Respir Investig. 2016; 54:494-499.
  10. Makiguchi T, Yamada M, Yoshioka Y, Sugiura H, Koarai A, Chiba S, Fujino N, Tojo Y, Ota C, Kubo H, Kobayashi S, Yanai M, Shimura S, Ochiya T, Ichinose M. Serum extracellular vesicular miR-21-5p is a predictor of the prognosis in idiopathic pulmonary fibrosis. Respir Res. 2016 5;17(1):110
  11. Motegi T, Takahashi T, Katsura H, Ichinose M, Nagai A. The development and validation of a new questionnaire to address the gap between the actual and desired states in COPD patients. Lung Dis Treat . 2016; 2:3.
  12. Müllerová H, HLandis S, Aisanov Z, Davis KJ, Ichinose M, Mannino DM, Maskell J, Menezes AM, van der Molen T, Oh Y-M, Tabberer M. Health behaviors and their correlates among participants in the Continuing to Confront COPD International Patient Survey. Int J of COPD. 2016; 11: 881-890.
  13. Numakura T, Tamada T, Nara M, Muramatsu S, Murakami K, Kikuchi T, Kobayashi M, Muroi M, Okazaki T, Takagi S, Eishi Y, Ichinose M. Simultaneous development of sarcoidossis and cutaneous vasculitis in a patient with refractory crohn’s disease during infliximab therapy. BMC Puulm Med. 2016; 16: 30.
  14. Sakamoto Y, Sakamoto K, Minakata Y, Shiba S, Takeshi Nakamura T, Ichinose M, Tajima F. Walking Pattern in COPD Patients. Rehabilitation Nursing 2016; 41: 211-217
  15. Sato K, Okada S, Sugawara A, Tode N, Watanuki Z, Suzuki K, Ichinose M. Improving physical activity ensures the long-term survival of pneumonia patients in a super-aged society: A retrospective study in an acute-care hospital in Japan. Tohoku J Exp Med. 2016; 238: 237-245
  16. Shishikura Y, Koarai A, Aizawa H, Yamaya M, Sugiura H, Watanabe M, Hashimoto Y, Numakura T, Makiguti T, Abe K, Yamada M, Kikuchi T, Hoshikawa Y, Okada Y, Ichinose M. Extracellular ATP is involved in dsRNA-induced MUC5AC production via P2Y2R in human airway epithelium. Respir Res. 2016; 17: 121
  17. Yamada M, Fujino N, Ichinose M. Inflammatory responses in the initiation of lung repair and regeneration: their role in stimulating lung resident stem cells. Inflammation and Regeneration 2016；36：15
  18. Tamada T, Sugiura H, Takahashi T, Matsunaga K, Kimura K, Katsumata U, Ohta K, Ichinose M. Coexisting COPD in elderly asthma with fixed airflow limitation: assessment by DLco %predicted and HRCT. J Asthma. 2016; 26: 1-9.
  19. Maruyama K, Inaba T, Tamada T, Kunikata H, Nakazawa T. Vitreous lavage fluid and bronchoalveolar lavage fluid have equal diagnostic value in sarcoidosis. Medicine (Baltimore). 95:e5531, 2016.
  20. Takada T, Mikami A, Kitamura N, Seyama K, Inoue Y, Nagai K, Suzuki M, Moriyama H, Akasaka K, Tazawa R, Hirai T, Mishima M, Hayashida M, Hirose M, Sugimoto C, Arai T, Hattori N, Watanabe K, Tamada T, Yoshizawa H, Akazawa K, Tanaka T, Yagi K,
    Young LR, McCormack FX, Nakata K. Efficacy and Safety of Long-term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis. Ann Am Thorac Soc. 13:1912-1922, 2016.

 

このページの先頭へ

 

2015年

  1. Ichinose M, Takizawa A, Izumoto T, Tadayasu Y, Hamilton AL, Kunz C, Fukuchi Y. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease. Int J COPD 2015; 10: 1673–1683.
  2. Kanai K, Koarai A, Shishikura Y, Sugiura H, Ichikawa T, Kikuchi T, Akamatsu K, Hirano T, Nakanishi M, Matsunaga K, Minakata Y, Ichinose M. Cigarette smoke augments MUC5AC production via the TLR3-EGFR pathway in airway epithelial cells. Respir Investig 2015; 53: 137-48.
  3. Matsunaga K, Hayata A, Akamatsu K, Hirano T, Tamada T, Kamei T, Tsuda T, Nakamura H, Takahashi T, Hozawa S, Mori Y, Sakamoto Y, Kimura K, Katsumata U, Miura M, Ichinose M. Stratifying the risk of COPD exacerbation using the modified Medical Research Council scale: a multicenter cross-sectional CAP study. Respir Investig 2015; 53: 82-85.
  4. Menezes AM, Landis SH, Han MK, Muellerova H, Aisanov Z, van der Molen T, Oh Y-M, Ichinose M, Mannino DM, Davis KJ. Continuing to Confront COPD International Surveys: comparison of patient and physician perceptions about COPD risk and management. Int J COPD 2015; 10: 159-172.
  5. Minakata Y, Morishita Y, Ichikawa T, Akamatsu K, Hirano T, Nakanishi M, Matsunaga K, Ichinose M. Effects of pharmacologic treatment based on airflow limitation and breathlessness on daily physical activity in patients with chronic obstructive pulmonary disease. Int J COPD 2015; 10: 1275-1282.
  6. Narumi S, Miki Y, Hata S, Ebina M, Saito M, Mori K, Kobayashi M, Suzuki T, Iwabuchi E, Sato I, Maemondo M, Endo C, Inoue A, Kondo T, Yamada-Okabe H, Ichinose M, Sasano H. Anterior gradient 2 is correlated with EGFR mutation in lung adenocarcinoma tissues. Int J Biol Markers 2015; 30: e234-242.
  7. Nihei M, Okazaki T, Ebihara S, Kobayashi M, Niu K, Gui P, Tamai T, Nukiwa T, Yamaya M, Kikuchi T, Nagatomi R, Ebihara T, Ichinose M. Chronic inflammation, lymphangiogenesis, and effect of an anti-VEGFR therapy in a mouse model and in human patients with aspiration pneumonia. J Pathol 2015; 235:632-645
  8. Ohta K, Ichinose M, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, Sakamoto W, Adachi M. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study. PLoS One 2015; 10: e0124109.
  9. Ono M, Ohkouchi S, Kanehira M, Tode N, Kobayashi M, Ebina M, Nukiwa T, Irokawa T, Ogawa H, Akaike T, Okada Y, Kurosawa H, Kikuchi T, Ichinose M. Mesenchymal Stem Cells Correct Inappropriate Epithelial-mesenchyme Relation in Pulmonary Fibrosis Using Stanniocalcin-1. Mol Ther .2015; 23: 549-560.
  10. Ohta C, Yamada M, Fujino N, Motohashi H, Tando Y, Takei Y, Suzuki T, Takahashi T, Kamata S, Makiguchi T, Yamaya M, Kubo H. Histone deacetylase inhibitor restores surfactant protein-c expression in alveolar-epithelial type ii cells and attenuates bleomycin-induced pulmonary fibrosis in vivo. Exp Lung Res. 2015; 19: 1-13.
  11. Tojo Y, Sekine H, Hirano I, Pan X, Souma T, Tsujita T, Kawaguchi S, Takeda N, Takeda K, Fong GH, Dan T, Ichinose M, Miyata T, Yamamoto M, Suzuki N. Hypoxia Signaling Cascade for Erythropoietin Production in Hepatocytes. Mol Cell Biol 2015; 35: 2658-2672.
  12. Tsukuya G, Matsumoto K, Fukuyama S, Crawford B, Nakanishi Y, Ichinose M, Machida K, Samukawa T, Ninomiya T, Kiyohara Y, Inoue H, on behalf of the Hisayama Pulmonary Physiology Study Group Validation of a COPD screening questionnaire and establishment of diagnostic cut-points in a Japanese general population: The Hisayama study. Allergol Int. 2015; 64: 49e53
  13. Santoso A, Kikuchi T, Tode N, Hirano T, Komatsu R, Damayanti T, Motohashi H, Yamamoto M, Kojima T, Uede T, Nukiwa T, Ichinose M. Syndecan 4 Mediates Nrf2-dependent Expansion of Bronchiolar Progenitors That Protect Against Lung Inflammation. Mol Ther. 2015; doi: 10.1038/mt.2015.153.
  14. Tamada T, Sugiura H, Takahashi T, Matsunaga K, Kimura K, Katsumata U, Takekoshi D, Kikuchi T, Ohta K, Ichinose M. Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations. Int J COPD 2015; 10: 2169-2176.
  15. Saito R, Suzuki T, Hiramoto K, Asami S, Naganuma E, Suda H, Iso T, Yamamoto H, Morita M, Furusawa Y, Negishi T, Ichinose M, Yamamoto M. Characterizations of Three Major Cysteine Sensors of Keap1 in Stress Response. Mol Cell Biol. 2015; 2: 00868-15
  16. Yamada Y, Ichinose M. Cutting edge of COPD therapy:current pharmacological therapy and future direction. COPD Res and Practice 2015; 1：5.
  17. Ohkouchi S, Ono M, Kobayashi M, Hirano T, Tojo Y, Ichinose M, Irokawa T, Ogawa H, Kurosawa H: Myriad functions of Stanniocalcin-1 (STC1) cover multiple therapeutic targets in the complicated pathogenesis of idiopathic pulmonary fibrosis (IPF). Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine. 2015 ;9(Suppl 1):91-6.
  18. Tamada T, Sugiura H, Takahashi T, Matsunaga K, Kimura K, Katsumata U, Takekoshi D, Kikuchi T, Ohta K ,Ichinose M: Biomarker-based detection of ACOS in COPD populations. Int J Chron Obstruct Pulmon Dis.2015:10, 2169-2176.
  19. Miyauchi E, Motoi N, Ichinose M, et al. Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin: Subtyping Based on Location and Expression of Transcription Factor TTF-1. Medicine. 94:e2324, 2015.

 

このページの先頭へ

 

2014年

  1. Guo Y, Niu K, Okazaki T, Wu H, Yoshikawa T, Ohrui T, Furukawa K, Ichinose M, Yanai K, Arai H, Huang G, Nagatomi R. Coffee treatment prevents the progression of sarcopenia in aged mice in vivo and in vitro. Exp Gerontol 2014;50:1-8
  2. Ichikawa T, Sugiura H, Koarai A, Minakata Y, Kikuchi T, Morishita Y, Oka A, Kanai K, Kawabata H, Hiramatsu M, Akamatsu K, Hirano T, Nakanishi M, Matsunaga K, Yamamoto N, Ichinose M. TLR3 activation augments matrix metalloproteinase production through reactive nitrogen species generation in human lung fibroblasts : J Immunol. 2014; 192(11):4977-4988.
  3. Kanehira M, Kikuchi T, Santoso A, Tode N, Hirano T, Ohkouchi S, Tamada T, Sugiura H, Harigae H, Ichinose M. Human marrow stromal cells downsize the stem cell fraction of lung cancers by fibroblast growth factor 10. Mol Cell Biol.2014:34(15):2848-2856.
  4. Kikuchi T, Kobashi Y, Hirano T, Tode N, Santoso A, Tamada T, Fujimura S, Mitsuhashi Y, Honda Y, Nukiwa T, Kaku M, Watanabe A, Ichinose M. Mycobacterium avium genotype is associated with the therapeutic response to lung infection. Clin Microbiol Infect 2014;20(3):256-262
  5. Kobayashi M, Sakakibara T, Inoue A, Fukuhara T, Sasano K, Ichinose M, Nukiwa T. An effective enrichment strategy for EML4-ALK fusion gene screening algorithm in non-small cell lung cancer patients. Respir Investig 2014;52(1):49-56
  6. Landis SH, Muellerova H, Mannino DM, Menezes AM, Han MK, van der Molen T, Ichinose M, Aisanov Z, Oh YM, Davis KJ. Continuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012-2013: Int J Chron Obstruct Pulmon Dis. 2014;9:597-611.
  7. Minakata Y, Sugino A, Kanda M, Ichikawa T, Akamatsu K, Koarai A, Hirano T, Nakanishi M, Sugiura H, Matsunaga K, Ichinose M. Reduced level of physical activity in Japanese patients with chronic obstructive pulmonary disease: Respir Investig 2014;52(1):41-48

 

このページの先頭へ
Copyright(C) Department of respiratory medicine,Tohoku Univ.All Rights Reserved.